ResMed Inc. (NYSE:RMD) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in ResMed Inc. (NYSE:RMD - Free Report) by 0.3% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 742,411 shares of the medical equipment provider's stock after purchasing an additional 2,406 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.51% of ResMed worth $181,237,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the business. UMB Bank n.a. grew its holdings in shares of ResMed by 1.9% in the third quarter. UMB Bank n.a. now owns 2,465 shares of the medical equipment provider's stock valued at $602,000 after purchasing an additional 47 shares in the last quarter. QRG Capital Management Inc. grew its holdings in shares of ResMed by 4.5% in the second quarter. QRG Capital Management Inc. now owns 1,291 shares of the medical equipment provider's stock valued at $247,000 after purchasing an additional 56 shares in the last quarter. Inspire Advisors LLC grew its holdings in shares of ResMed by 1.9% in the second quarter. Inspire Advisors LLC now owns 3,060 shares of the medical equipment provider's stock valued at $586,000 after purchasing an additional 56 shares in the last quarter. Concurrent Investment Advisors LLC grew its holdings in shares of ResMed by 3.1% in the third quarter. Concurrent Investment Advisors LLC now owns 1,919 shares of the medical equipment provider's stock valued at $469,000 after purchasing an additional 57 shares in the last quarter. Finally, Moss Adams Wealth Advisors LLC grew its holdings in shares of ResMed by 2.0% in the third quarter. Moss Adams Wealth Advisors LLC now owns 3,043 shares of the medical equipment provider's stock valued at $743,000 after purchasing an additional 60 shares in the last quarter. Institutional investors and hedge funds own 54.98% of the company's stock.

ResMed Stock Performance

RMD stock traded down $0.31 on Friday, hitting $249.02. The company's stock had a trading volume of 351,327 shares, compared to its average volume of 842,042. The firm has a 50 day moving average of $242.24 and a two-hundred day moving average of $225.66. ResMed Inc. has a 1 year low of $156.39 and a 1 year high of $260.49. The stock has a market cap of $36.56 billion, a price-to-earnings ratio of 32.98, a price-to-earnings-growth ratio of 1.81 and a beta of 0.69. The company has a current ratio of 2.92, a quick ratio of 1.91 and a debt-to-equity ratio of 0.13.

ResMed (NYSE:RMD - Get Free Report) last released its quarterly earnings results on Thursday, October 24th. The medical equipment provider reported $2.20 EPS for the quarter, beating the consensus estimate of $2.03 by $0.17. ResMed had a net margin of 23.15% and a return on equity of 25.53%. The firm had revenue of $1.22 billion during the quarter, compared to the consensus estimate of $1.19 billion. During the same quarter in the prior year, the firm earned $1.64 EPS. ResMed's revenue for the quarter was up 11.1% on a year-over-year basis. Equities analysts predict that ResMed Inc. will post 9.28 EPS for the current fiscal year.

ResMed Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 12th. Shareholders of record on Thursday, November 7th will be given a dividend of $0.53 per share. The ex-dividend date is Thursday, November 7th. This represents a $2.12 dividend on an annualized basis and a yield of 0.85%. ResMed's payout ratio is currently 28.08%.

Insiders Place Their Bets

In other ResMed news, CEO Michael J. Farrell sold 14,683 shares of the company's stock in a transaction on Monday, September 9th. The shares were sold at an average price of $248.38, for a total transaction of $3,646,963.54. Following the completion of the transaction, the chief executive officer now owns 464,169 shares in the company, valued at approximately $115,290,296.22. This represents a 3.07 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Kaushik Ghoshal sold 5,000 shares of the company's stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $252.56, for a total transaction of $1,262,800.00. Following the transaction, the insider now owns 21,788 shares of the company's stock, valued at approximately $5,502,777.28. The trade was a 18.67 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 68,334 shares of company stock worth $16,379,713. 0.71% of the stock is owned by insiders.

Analyst Ratings Changes

A number of brokerages recently weighed in on RMD. StockNews.com upgraded shares of ResMed from a "hold" rating to a "buy" rating in a report on Tuesday, October 15th. Bank of America boosted their price target on shares of ResMed from $240.00 to $270.00 and gave the stock a "buy" rating in a report on Thursday, September 26th. Royal Bank of Canada boosted their price target on shares of ResMed from $224.00 to $232.00 and gave the stock a "sector perform" rating in a report on Friday, October 25th. KeyCorp boosted their price target on shares of ResMed from $251.00 to $266.00 and gave the stock an "overweight" rating in a report on Friday, October 25th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of ResMed in a report on Friday, October 25th. One analyst has rated the stock with a sell rating, five have given a hold rating, six have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $225.70.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.